Alzheimer’s disease is a neurodegenerative, progressive, non-reversible disorder. Alzheimer’s disease is caused due to abnormal functioning of brain cells i.e. failure of synaptic transmission, resulting in the loss of cognitive functions. Some of the signs and symptoms of alzheimer’s disease are memory loss, insomnia, repetitive movements, agitation, anxiety, depression and loss of reasoning abilities. All memory and mental functioning may be lost in advanced stages of the disease. Alzheimer’s disease may lead to death. According to National Institute of Aging, Alzheimer’s disease is the common form of dementia.
Population aging across the globe is a major factor driving the market for Alzheimer’s therapeutics and diagnostics. Rising life expectancy is contributing to quick increases in number of aged population, and is associated with increased prevalence of chronic diseases like dementia. Therapies for AD offer temporary and uncertain improvements in the well-being of individuals, and none of the approved drugs can modify the course of the disease advancement. Thus, the magnitude of the affected population and lack of suitable and effective treatment offers an incredible opportunity for drug manufacturers.
However, identification of the primary reasons and mechanisms involved in AD are is limited. Drug manufacturers have been unable to validate significant clinical benefits of treatment for a numerous of new compounds due to strict regulations. One of the significant trend observed in this market is collaboration of the existing players. Precisely, diagnostic technology companies are carefully trying to bring about effective biomarker technologies to support and improve the drug development process for potential drug candidates which is further expected to propel the demand.
North America dominates the global market for alzheimer’s disease therapeutics due to large number of aging population. Asia followed by the Europe are expected to show high growth rates in the next five years in the global alzheimer’s disease therapeutics market. China and India are expected to be the fastest growing alzheimer’s disease therapeutics markets in Asia-Pacific region. Some of the key driving forces for alzheimer’s disease therapeutics market in emerging countries are increasing R&D investment, large pool of patients and improvement of healthcare infrastructure.
In 2018, the global Alzheimers Disease Therapeutics market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.
This report focuses on the global Alzheimers Disease Therapeutics status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Alzheimers Disease Therapeutics development in United States, Europe and China.
The key players covered in this study
F. Hoffmann-La Roche
Market segment by Type, the product can be split into
NMDA Receptor Antagonists
Market segment by Application, split into
Market segment by Regions/Countries, this report covers
Central & South America
The study objectives of this report are:
To analyze global Alzheimers Disease Therapeutics status, future forecast, growth opportunity, key market and key players.
To present the Alzheimers Disease Therapeutics development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.
Table of Contents
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.4.1 Global Alzheimers Disease Therapeutics Market Size Growth Rate by Type (2014-2025)
1.4.3 Cholinesterase Inhibitors
1.4.4 NMDA Receptor Antagonists
1.5 Market by Application
1.5.1 Global Alzheimers Disease Therapeutics Market Share by Application (2014-2025)
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Alzheimers Disease Therapeutics Market Size
2.2 Alzheimers Disease Therapeutics Growth Trends by Regions
2.2.1 Alzheimers Disease Therapeutics Market Size by Regions (2014-2025)
2.2.2 Alzheimers Disease Therapeutics Market Share by Regions (2014-2019)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Opportunities
12 International Players Profiles
12.1 F. Hoffmann-La Roche
12.1.1 F. Hoffmann-La Roche Company Details
12.1.2 Company Description and Business Overview
12.1.3 Alzheimers Disease Therapeutics Introduction
12.1.4 F. Hoffmann-La Roche Revenue in Alzheimers Disease Therapeutics Business (2014-2019)
12.1.5 F. Hoffmann-La Roche Recent Development
12.2.1 Merck Company Details
12.2.2 Company Description and Business Overview
12.2.3 Alzheimers Disease Therapeutics Introduction
12.2.4 Merck Revenue in Alzheimers Disease Therapeutics Business (2014-2019)
12.2.5 Merck Recent Development
12.3.1 Pfizer Company Details
12.3.2 Company Description and Business Overview
12.3.3 Alzheimers Disease Therapeutics Introduction
12.3.4 Pfizer Revenue in Alzheimers Disease Therapeutics Business (2014-2019)
12.3.5 Pfizer Recent Development
12.4.1 Novartis Company Details
12.4.2 Company Description and Business Overview
12.4.3 Alzheimers Disease Therapeutics Introduction
12.4.4 Novartis Revenue in Alzheimers Disease Therapeutics Business (2014-2019)
12.4.5 Novartis Recent Development
12.5.1 Eisai Company Details
12.5.2 Company Description and Business Overview
12.5.3 Alzheimers Disease Therapeutics Introduction
12.5.4 Eisai Revenue in Alzheimers Disease Therapeutics Business (2014-2019)
12.5.5 Eisai Recent Development
12.6.1 Actavis Company Details
12.6.2 Company Description and Business Overview
12.6.3 Alzheimers Disease Therapeutics Introduction
12.6.4 Actavis Revenue in Alzheimers Disease Therapeutics Business (2014-2019)
12.6.5 Actavis Recent Development
12.7 Daiichi Sankyo
12.7.1 Daiichi Sankyo Company Details
12.7.2 Company Description and Business Overview
12.7.3 Alzheimers Disease Therapeutics Introduction
12.7.4 Daiichi Sankyo Revenue in Alzheimers Disease Therapeutics Business (2014-2019)
12.7.5 Daiichi Sankyo Recent Development
Contact Us: Sales@Wiseguyreports.Com Ph: +1-646-845-9349 (Us) Ph: +44 208 133 9349 (Uk)
Company Name: Wiseguyreports.com
Contact Person: Norah Trent
Email: Send Email
Phone: +1 646 845 9349, +44 208 133 9349